Study Demonstrates Restylane(R) Effect Lasted 18 Months In 97% Of Patients With One Repeat Injection
Main Category: DermatologyAlso Included In: Regulatory Affairs / Drug Approvals; Clinical Trials / Drug Trials
Article Date: 11 Feb 2009 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Recent clinical data show that Restylane(R) lasted 18 months in 97% of patients with one repeat injection. Restylane(R) is the only HA filler with an 18-month FDA-approved duration claim.
These data were generated in a controlled, randomized, evaluator-blinded study that assessed the safety and effectiveness of two different retreatment schedules, 4.5 months or 9 months, after initial treatment of nasolabial folds (NLF). Patients were evaluated using the Wrinkle Severity Rating Scale (WSRS), a five-point scale to measure visual severity of wrinkles where five is the most severe rating (extreme). 92% of patients were naive to dermal fillers so had no residual effects from earlier treatment.
Key findings from the study include:
-- At 18 months, 97% of patients continued to show improvement in NLF correction with one repeat injection
-- Correction with Restylane(R) lasted for 18 months, regardless of retreatment schedule
-- At 18 months, patients still had a 1.7 grade improvement in WSRS over baseline
-- Adverse events were primarily swelling (24%) and bruising (19%); none were serious.
For more information, please contact Ilisa Wirgin or Elyse Koenig of LaForce + Stevens at 212.242.9353 x 140/167.
Restylane(R) is available only through a licensed practitioner. Complete product and safety information is available at http://www.RestylaneUSA.com.
Safety information
Restylane(R) is indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. The most commonly observed side effects are swelling, redness, pain, bruising, and tenderness at the injection site, which typically resolve in less than seven days. Avoid exposure of the treated area to excessive sun and UV lamp exposure and extreme cold weather until any initial swelling and redness have resolved. Safety has not been established for use during pregnancy, when breastfeeding, or in patients under 18 years.
Restylane is a trademark of HA North American Sales AB.
Medicis Aesthetics Inc.
http:// www.medicis.com
Visit our dermatology section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/138541.php>
APA
http://www.medicalnewstoday.com/releases/138541.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



